CPHI & PMEC Shenzhen 2025: A Gateway to the Greater Bay Area Pharma Market

2025-08-07

In 2024, China's pharma exports showed scale expansion, structural optimization, and diversified market development. As the pharma industry internationalizes and develops with high quality, innovative and biopharmaceuticals are driving export growth, with overseas models diversifying. With emerging markets rising, the export potential of China's pharma products will be further unlocked, bringing greater market opportunities to pharma companies. As one of China's core pharma industry expos, CPHI & PMEC Shenzhen 2025 will be held in early September in Shenzhen. Themed "Bay Area Synergy—Building a Global Biopharma Resilience Ecosystem", it aligns with national policies in medicine, biotech, and AI + technology. Based in Shenzhen, it radiates across the Greater Bay Area and globally, offering a high - quality platform for the international pharma industry chain. The expo focuses on the Southeast Asian pharma market's international layout, analyzing regional pharma trade trends and investment opportunities. It will cover the entire Asia - Pacific region and the Belt and Road areas, focusing on new drug R & D, smart manufacturing, and process innovation. Gathering cutting - edge industry forces, it showcases innovative achievements and solutions, and collaboratively outlines a new blueprint for the Greater Bay Area's pharma industry.

Date :
Sep. 1-3, 2025

Venue:
Shenzhen Convention and Exhibition Center (Futian)

Official link:
[https://www.cphi.com/china/en-gb/home.html](https://www.cphi.com/china/en-gb/home.html)

3 Highlights Worth the Pharma Industry's Attention:

1. GBA Policy and Industrial Cluster Dual Drivers

Shenzhen, Guangzhou, Zhongshan, and Zhuhai have become key hubs for raw chemicals, biopharmaceuticals, and medical devices. The expo is a vital platform for domestic - international resource integration.

2. Beauty Ingredients & CXO Emerging Sectors

Non - surgical aesthetic projects are growing at a 16.11% CAGR (2023 - 2030),with the market size expected to surpass 146.1 billion yuan by 2030. This Shenzhen expo introduces a beauty supply chain zone for the first time, creating a cross - sectoral innovation and trade fair integrating medicine, cosmetics, and medical devices. It explores differentiated growth paths and opens up new development spaces for the aesthetic industry.

3. Deepened International Cooperation & Omnichannel Digital Marketing

In recent years, the "Belt and Road" region has become a hot spot for market expansion following the Euro - American markets. To help Chinese pharma enterprises consolidate their position in high - end overseas markets and tap into emerging market opportunities, CPHI & PMEC China are actively establishing strategic collaborations with associations and media in multiple countries and regions, including India, Indonesia, Thailand, Malaysia, Japan, S. Korea, Singapore, Vietnam, Russia, the US, Germany, and Brazil. Relying on CPHI's global resources, this expo has connected with over 200 high - quality partners in key regions such as Hong Kong and Macao, Europe and America, Japan and Korea, Southeast Asia, and the Middle East. It has also partnered with local industry associations in S. Korea, Indonesia, Vietnam, etc. In terms of international audience expansion. In addition, the expo employs omnichannel digital marketing to build a multi - platform social media promotion network, reaching buyers in the dietary supplements, functional foods, cosmetics, and pharmaceutical fields, and facilitating precise business connections for natural ingredients enterprises.

Our observation perspective:

At the upcoming CPHI Shenzhen 2025 expo, the peptide sector will be a major focus. Peptides are increasingly used in biopharmaceuticals and health tech, especially in drug R&D, innovative therapies, and health product development. With global demand for peptide drugs rising, the expo offers a great exchange and collaboration platform for peptide - related companies, researchers, and investors.